Retiring the outdated formula for obesity treatment
Retiring the outdated formula for obesity treatment
Decades of effort to control obesity have failed, leading to cascading health problems for hundreds of millions and an ever-growing burden of care associated with the health risks obesity poses.
Although drugs approved for weight management such as Zepbound and Wegovy offer our best hope to halt obesity, reversing its rise requires addressing all drivers of obesity through a combination of coaching, technology, lifestyle changes, smart policy and—yes—drugs.
What will it take to limit obesity’s footprint?
What will it take to limit obesity’s footprint?
- Accept it’s a disease
- Pursue mass market now
- Align payers around GLP-1s
- Address obesity’s drivers
Healthcare providers and payers must recognize obesity as a chronic disease
Healthcare providers and payers must recognize obesity as a chronic disease
While doctors may recognize obesity as a disease in the abstract, too many continue to treat it as a product of bad behavior. Reversing its course will demand individualized treatment solutions that leverage every tool at our disposal.
HEALTHCARE
Obesity is a public health crisis: Pharma needs a commercial model that can solve it
We finally have safe, effective treatments for obesity in the form of GLP-1s. We believe pharma needs to pursue a strategy to get these to the patients who need them most.
HEALTHCARE
Obesity is a public health crisis: Pharma needs a commercial model that can solve it
We finally have safe, effective treatments for obesity in the form of GLP-1s. We believe pharma needs to pursue a strategy to get these to the patients who need them most.
“We’ve reached a turning point in how the healthcare system treats obesity. What isn’t clear is if we have the will to act on it while there’s still time to influence public health.”
Howard Deutsch, principal, ZS
“We’ve reached a turning point in how the healthcare system treats obesity. What isn’t clear is if we have the will to act on it while there’s still time to influence public health.”
Howard Deutsch, principal, ZS
- G1
- G2
Featured insights on obesity’s next chapter
Featured insights on obesity’s next chapter
The next wave of obesity medications must solve more than just weight loss
In obesity, overemphasis on weight loss alone may lead to market commoditization. Manufacturers must differentiate through innovation, personalized treatment approaches and broader clinical benefits.
The next wave of obesity medications must solve more than just weight loss
In obesity, overemphasis on weight loss alone may lead to market commoditization. Manufacturers must differentiate through innovation, personalized treatment approaches and broader clinical benefits.
Consumer choice is shaping the weight management market
In this webinar, we get into the data on what drives consumer decision-making for weight loss management solutions.
GLP-1s give us a path to beating obesity
Decades of effort to control obesity through exercise, dieting, surgery and drugs have failed. GLP-1s offer new hope for those struggling with weight management, but solving this public health crisis will require a new treatment paradigm.
GLP-1s give us a path to beating obesity
Decades of effort to control obesity through exercise, dieting, surgery and drugs have failed. GLP-1s offer new hope for those struggling with weight management, but solving this public health crisis will require a new treatment paradigm.
Obesity is a public health crisis
As long as GLP-1s are priced at or near current levels, their clinical benefits will be beside the point. Manufacturers need to dramatically lower their prices and adopt a mass market commercial model that prioritizes population health.
One patient’s obesity journey
Even as powerful drugs emerge to treat obesity, stigmas persist against those living with the condition. One patient shares her personal journey.
Payer strategies for GLP-1 coverage
GLP-1 drugs such as Wegovy and Zepbound pose an acute challenge to health plan finances. Here are 3 strategies payers can use to guide decision-making and manage coverage decisions for weight-loss medications.
In the news
In the news
Want to know what’s happening in obesity?
Want to know what’s happening in obesity?
Connect with our experts
Connect with our experts
Frequently asked questions about obesity treatment today
Frequently asked questions about obesity treatment today
Why must pharma prioritize “weight management” over “weight loss” to solve obesity?
What is the risk to pharma if it maintains the status quo with GLP-1s for obesity?
What strategies should pharma pursue to boost supply of GLP-1s for obesity?
After Wegovy and Zepbound, what weight-loss drugs are currently in development?
Why must pharma prioritize “weight management” over “weight loss” to solve obesity?
Not every patient struggling with their weight should be prescribed a GLP-1, and not everyone with obesity needs to be on the most potent weight-loss drug. Pharma, payers and health systems must collaborate to develop guidelines and lines of therapy based on clinical evidence, population health goals and financial constraints. These guidelines and lines of therapy must consider “drug plus” solutions that integrate beyond-the-pill weight-management innovations across the patient journey.
What is the risk to pharma if it maintains the status quo with GLP-1s for obesity?
It’s impossible to predict how governments and others will respond, but these are some potential risks to pharma if the status quo holds: Employers and governments will define access narrowly, meaning fewer patients will benefit and the crisis will worsen. One of the companies working on oral, small-molecule GLP-1s will decide to pursue the mass market and push out higher-priced competitors. U.S. and European regulators could warm to the idea of drugs manufactured in China, where a handful of GLP-1s are under development. Countries could take things into their own hands by invalidating patents or developing their own homegrown molecules. Eventually, semaglutide and terzepatide will lose exclusivity, prices will fall and supply will come online. Unfortunately, by this time, it may already be too late to solve the obesity public health crisis.
If even one of these hypotheticals comes to pass, the pharmaceutical industry will lose its chance to participate in the full scope of the obesity opportunity, leading to serious reputational harm by failing to solve the signature public health crisis of our day.
What strategies should pharma pursue to boost supply of GLP-1s for obesity?
Obesity affects more than a billion people globally. GLP-1 manufacturers should start opening up supply by forecasting demand based on the true size of the opportunity, not today’s access- and affordability-restricted one. Pharma also should push for public-private coinvestment in the supply chain, consider licensing technology to contract manufacturers and commit to rapidly digitalizing its supply chain for these drugs to better predict (and correct for) challenges and vulnerabilities.
After Wegovy and Zepbound, what weight-loss drugs are currently in development?
There are more than 70 drugs for obesity treatment currently in development, including at least eight in phase 3 trials. These drugs use a variety of mechanisms of action and cover a range of routes of administration, including injectables, orals and linguals. Manufacturers include established market leaders, such as Eli Lilly and Novo Nordisk, as well as Chinese pharmaceutical companies and emerging biotechs.